Blood pressure and renal hemodynamic responses to acute angiotensin II infusion are enhanced in a female mouse model of systemic lupus erythematosus

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 301, Issue 5, 2011, Pages

  Venegas Pont, Marcia ^a   Mathis, Keisa W ^a   Iliescu, Radu ^a,b   Ray, William H ^a   Glover, Porter H ^a   Ryan, Michael J ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Angiotensin receptor; Autoimmune; Inflammation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; LOSARTAN; RENIN;

ANESTHESIA INDUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; EXPERIMENTAL MOUSE; FEMALE; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRESSOR RESPONSE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; FEMALE; HYPERTENSION; INFUSIONS, INTRA-ARTERIAL; KIDNEY; LOSARTAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED NZB; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENAL CIRCULATION; RNA, MESSENGER; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 80155169933     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00079.2011     Document Type: Article

References (54)

1. Al-Awadhi AM, Haider MZ, Sharma PN, Hasan EA, Botaiban F, Al-Herz A, Nahar I, Al-Enezi H, Al-Saeid K. Angiotensin-converting enzyme gene polymorphism in Kuwaiti patients with systemic lupus erythematosus. Clin Exp Rheumatol 25: 437-442, 2007.
2. Alexanderson E, Ochoa JM, Calleja R, Juarez-Rojas JG, Prior JO, Jacome R, Romero E, Meave A, Posadas-Romero C. Endothelial dysfunction in systemic lupus erythematosus: evaluation with 13N-ammonia PET. J Nucl Med 51: 1927-1931, 2010.
3. Bagi Z, Hamar P, Kardos M, Koller A. Lack of flow-mediated dilation and enhanced angiotensin II-induced constriction in skeletal muscle arterioles of lupus-prone autoimmune mice. Lupus 15: 326-334, 2006.
4. Boumpas DT, Austin HA, III, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 122: 940-950, 1995.
5. Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 51: 1583-1589, 1997.
6. Crowley SD, Vasievich MP, Ruiz P, Gould SK, Parsons KK, Pazmino AK, Facemire C, Chen BJ, Kim HS, Tran TT, Pisetsky DS, Barisoni L, Prieto-Carrasquero MC, Jeansson M, Foster MH, Coffman TM. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest 119: 943-953, 2009.
7. De Albuquerque DA, Saxena V, Adams DE, Boivin GP, Brunner HI, Witte DP, Singh RR. An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis. Kidney Int 65: 846-859, 2004.
8. Dubois EL, Horowitz RE, Demopoulos HB, Teplitz R. NZB/NZW mice as a model of systemic lupus erythematosus. JAMA 195: 285-289, 1966.
9. Duran-Barragan S, McGwin G Jr, Vila LM, Reveille JD, Alarcon GS. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus-results from LUMINA (LIX): a multiethnic U.S. cohort. Rheumatology (Oxford) 47: 1093-1096, 2008.
10. Geers AB, Koomans HA, Roos JC, Boer P, Dorhout Mees EJ. Functional relationships in the nephrotic syndrome. Kidney Int 26: 324-330, 1984.
11. Guo Q, Lu X, Miao L, Wu M, Lu S, Luo P. Analysis of clinical manifestations and pathology of lupus nephritis: a retrospective review of 82 cases. Clin Rheumatol 29: 1175-1180, 2010.
12. Herlitz H, Svalander C, Tarkowski A, Westberg G. Effect of captopril on murine systemic lupus erythematosus disease. J Hypertens Suppl 6: S684-S686, 1988.
13. Herlitz H, Tarkowski A, Svalander C, Volkmann R, Westberg G. Beneficial effect of captopril on systemic lupus erythematosus-like disease in MRL lpr/lpr mice. Int Arch Allergy Appl Immunol 85: 272-277, 1988.
14. Herrera-Acosta J, Guerrero J, Erbessd ML, Paz-Barahona M, Chessal F, Alarcon-Segovia D, Pena JC. Normotensive hyperreninemia in systemic lupus erythematosus. An indicator of tubular dysfunction. Nephron 22: 128-137, 1978.
15. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 92: 3521-3525, 1995.
16. Johnson SR, Harvey PJ, Floras JS, Iwanochko M, Ibanez D, Gladman DD, Urowitz M. Impaired brachial artery endothelium dependent flowmediated dilation in systemic lupus erythematosus: preliminary observations. Lupus 13: 590-593, 2004.
17. Kanda H, Kubo K, Tateishi S, Sato K, Yonezumi A, Yamamoto K, Mimura T. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 14: 288-292, 2005.
18. Kiberd BA. Murine lupus nephritis. A structure-function study. Lab Invest 65: 51-60, 1991.
19. Kiley J, Zager P. Hyporeninemic hypoaldosteronism in two patients with systemic lupus erythematosus. Am J Kidney Dis 4: 39-43, 1984.
20. Kimberly RP, Gill JR Jr, Bowden RE, Keiser HR Plotz PH. Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erythematosus. Ann Intern Med 89: 336-341, 1978.
21. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. Angiotensin-converting enzyme insertion/deletion polymorphism and systemic lupus erythematosus: a metaanalysis. J Rheumatol 33: 698-702, 2006.
22. Lima DS, Sato EI, Lima VC, Miranda F Jr, Hatta FH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 29: 292-297, 2002.
23. Macanovic M, Sinicropi D, Shak S, Baughman S, Thiru S, Lachmann PJ. The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 106: 243-252, 1996.
24. Macanovic M, Sinicropi D, Shak S, Baughman S, Thiru S, Lachmann PJ. The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 106: 243-252, 1996.
25. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145: 408-415, 1997.
26. Metsarinne KP, Nordstrom DC, Konttinen YT, Teppo AM, Fyhrquist FY. Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int 12: 93-96, 1992.
27. Molad Y, Gal E, Magal N, Sulkes J, Mukamel M, Weinberger A, Lalazari S, Shohat M. Renal outcome and vascular morbidity in systemic lupus erythematosus (SLE): lack of association with the angiotensinconverting enzyme gene polymorphism. Semin Arthritis Rheum 30: 132-137, 2000.
28. Nakano M, Ueno M, Hasegawa H, Watanabe T, Kuroda T, Ito S, Arakawa M. Renal haemodynamic characteristics in patients with lupus nephritis. Ann Rheum Dis 57: 226-230, 1998.
29. Okudaira H, Terada E, Okudaira K. Animal models utilized in the research of autoimmune disease control: experimental therapy of glomerulonephritis in NZB/W F1 mice. Prog Clin Biol Res 229: 157-174, 1987.
30. Parsa A, Lovett DH, Peden EA, Zhu L, Seldin MF, Criswell LA. Renin-angiotensin system gene polymorphisms predict the progression to renal insufficiency among Asians with lupus nephritis. Genes Immun 6:217-224, 2005.
31. Parsa A, Peden E, Lum RF, Seligman VA, Olson JL, Li H, Seldin MF, Criswell LA. Association of angiotensin-converting enzyme polymor- phisms with systemic lupus erythematosus and nephritis: analysis of 644 SLE families. Genes Immun 3 Suppl 1: S42-S46, 2002.
32. Perez De LG, De WC, Cohen CD, Nieto E, Molina A, Banas B, Luckow B, Vicente AB, Mampaso F, Schlondorff D. Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice. J Pharmacol Exp Ther 307: 275-281, 2003.
33. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93: 513-519, 1992.
34. Prkacin I, Novak B, Sertic J, Mrzljak A. Angiotensin-converting enzyme gene polymorphism in patients with systemic lupus. Acta Med Croatica 55: 73-76, 2001.
35. Rahman P, Aguero S, Gladman DD, Hallett D, Urowitz MB. Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus 9: 672-675, 2000.
36. Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E, Chakrabarti A, Richardson BC, Shelden E, McCune WJ, Kaplan MJ. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 103: 3677-3683, 2004.
37. Rudofsky UH, Dilwith RL, Magro AM, Roths JB. Low plasma renin activity in lupus-prone mice: a metabolic abnormality in MRL/Mp-lpr/lpr mice? Arthritis Rheum 28: 599-600, 1985.
38. Rudofsky UH, Dilwith RL, Roths JB, Lawrence DA, Kelley VE, Magro AM. Differences in the occurrence of hypertension among (NZB X NZW)F1, MRL-lpr, and BXSB mice with lupus nephritis. Am J Pathol 116: 107-114, 1984.
39. Ryan MJ, Jernigan NL, Drummond HA, McLemore GR Jr, Rimoldi JM, Poreddy SR, Gadepalli RS, Stec DE. Renal vascular responses to CORM-A1 in the mouse. Pharmacol Res 54: 24-29, 2006.
40. Ryan MJ, McLemore, GR Jr. Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 292: R736-R742, 2007.
41. Ryan MJ, McLemore, GR Jr, Hendrix ST. Insulin resistance and obesity in a mouse model of systemic lupus erythematosus. Hypertension 48: 988-993, 2006.
42. Salvati P, Lamberti E, Ferrario R, Ferrario RG, Scampini G, Pugliese F, Barsotti P, Patrono C. Long-term thromboxane-synthase inhibition prolongs survival in murine lupus nephritis. Kidney Int 47: 1168-1175, 1995.
43. Skamra C, Ramsey-Goldman R. Management of cardiovascular complications in systemic lupus erythematosus. Int J Clin Rheumtol 5: 75-100, 2010.
44. Sprovieri SR, Sens YA. Polymorphisms of the renin-angiotensin system genes in Brazilian patients with lupus nephropathy. Lupus 14: 356-362, 2005.
45. Sprovieri SR, Sens YA, Martini FD. Association between polymorphisms of the renin-angiotensin system and more severe histological forms of lupus nephritis. Clin Nephrol 64: 20-27, 2005.
46. Stec DE, Vera T, Storm MV, McLemore GR Jr, Ryan MJ. Blood pressure and renal blow flow responses in heme oxygenase-2 knockout mice. Am J Physiol Regul Integr Comp Physiol 297: R1822-R1828, 2009.
47. Tam LS, Fan B, Li EK, Thomas GN, Yim SF, Haines CJ, Tomlinson B. Patients with systemic lupus erythematosus show increased platelet activation and endothelial dysfunction induced by acute hyperhomocysteinemia. J Rheumatol 30: 1479-1484, 2003.
48. Thacker SG, Duquaine D, Park J, Kaplan MJ. Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells. Lupus 19: 288-299, 2010.
49. Trachtman H, Ginzler E, Tejani A, Rao M, Herrod L, Finberg L. Abnormal antidiuretic hormone secretion in patients with systemic lupus erythematosus. Nephron 46: 67-72, 1987.
50. Uhm WS, Lee HS, Chung YH, Kim TH, Bae SC, Joo KB, Kim TY, Yoo DH. Angiotensin-converting enzyme gene polymorphism and vascular manifestations in Korean patients with SLE. Lupus 11: 227-233, 2002.
51. Urowitz MB, Gladman DD, Ibanez D, Berliner Y. Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study. Ann Rheum Dis 65: 115-117, 2006.
52. Urushihara M, Kondo S, Kagami S, Kobori H. Urinary angiotensinogen accurately reflects intrarenal renin-angiotensin system activity. Am J Nephrol 31: 318-325, 2010.
53. Venegas-Pont M, Manigrasso MB, Grifoni SC, LaMarca BB, Maric C, Racusen LC, Glover PH, Jones AV, Drummond HA, Ryan MJ. Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension 56: 643-649, 2010.
54. Venegas-Pont M, Sartori-Valinotti JC, Maric C, Racusen LC, Glover PH, McLemore GR Jr, Jones AV, Reckelhoff JF, Ryan MJ. Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 296: R1282-R1289, 2009.